A Phase II, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT 1303 in Subjects with Moderate to Severe Active Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Amiselimod (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 12 Oct 2016 Status changed from recruiting to completed.
- 01 Apr 2016 Planned End Date changed from 1 Aug 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov.
- 01 Apr 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov.